PD-1信号通路在非小细胞肺癌中的研究进展

免疫治疗是目前除手术、化疗、放疗及靶向治疗外,另一种能够有效改善肺癌预后的治疗方法。在各种免疫治疗方法中,免疫检查点抑制剂(immune checkpoint inhibitors,ICI)在近年来发展迅速,已成为肿瘤治疗领域的新兴疗法及研究热点。其中,程序性死亡受体1(programmed death receptor 1,PD 1)及其配体程序性死亡配体 1(programmed death receptor ligand1,PD L1)的抑制剂在多种恶性肿瘤的治疗中均取得了显著疗效,部分药物已被美国FDA批准应用于临床。该文对PD 1／PD L1抑制剂在晚期非小细胞肺癌(non small cell lung cancer,NSCLC)患者治疗中的临床研究现状进行综述,探讨其在晚期NSCLC治疗中的临床应用价值、前景及面临的问题与挑战。

Research Progress of PD1 pathway in Non-small-cell lung cancer

Immunotherapy is a new method that can effectively improve the prognosis of lung cancer, in addition to surgery therapy, chemotherapy, radiotherapy and targeted therapy. In recent years, immune checkpoint inhibitors develop rapidly and have been the research hotspots among various immunotherapies. The inhibitors of programmed death receptor-1 and its ligand programmed death receptor-ligand 1 have achieved significant effects in multiple malignancies. Some of them have been approved for clinical treatments by FAD. This paper reviews clinical advances of PD-1/PD-L1 pathway inhibitors in NSCLC to explore its clinical application value, prospect, problems and challenges.